Kathleen M. Darcy

Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group

Michael A. Bookman, Kathleen M. Darcy, Daniel L. Clarke‐Pearson et al. · Journal of Clinical Oncology · 2003 · 613 citations

Medicine, Gynecology, Oncology +17

Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study

Carol Aghajanian, Michael W. Sill, Kathleen M. Darcy et al. · Journal of Clinical Oncology · 2011 · 319 citations · Full text

Medicine, Gynecology, Oncology +16

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study

Gini F. Fleming, Michael W. Sill, Kathleen M. Darcy et al. · Gynecologic Oncology · 2009 · 298 citations · Full text

Medicine, Gynecology, Oncology +8

Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study

Russell J. Schilder, Michael W. Sill, Xiaowei Chen et al. · Clinical Cancer Research · 2005 · 259 citations · Full text

Medicine, Oncology, Pharmacology +17

Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study

D. Scott McMeekin, David Tritchler, David E. Cohn et al. · Journal of Clinical Oncology · 2016 · 213 citations

Medicine, Gynecology, Oncology +17